Positioning political buying, disclosed 2026-08-19
Options no verdict drawn today, left as found
Ethical passes the values gate
Price74.16 USD
Fair value109.38
Ethical score70.0/100
Our investment reviews on this name
2026-08-31Read Markup85.94-13.7% to today
2026-07-02Read Distribution80.39-7.7% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Globus Medical Inc holds its Markdown at $74.16. The statistical read favours the sellers, held for 18 days.
As held on the ledger · 2026-09-17
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 18 days
Price at the screen
$74.16
Valuation
18.97 trailing · 13.74 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.96
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.24%
Below 33%
Interest-bearing debt is just 2.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.66%
Below 33%
Cash held in interest-bearing accounts and securities is 0.7% of assets, under the one-third limit.
Pass
Receivables
22.73%
Below 49%
Money owed to the company is 22.7% of assets, under the 49% limit.
Pass
Revenue purity
0.24%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-17 screen. The gold marker is the market price at the same screen. A 47.5% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Spine hardware that must outlast the patient
When a surgeon rebuilds a damaged spine the screws and plates must stay put for decades. Globus Medical builds those implants and has lifted revenue 27 percent while keeping a 19 percent profit margin. At 15 times forward earnings the shares sit well below our fair value of 108.90, yet the opportunity rating stays at none.
The business clears our ethical screen and carries a narrow moat in a steady medical niche. Twelve analysts rate the stock a buy with a 104 median target, but the modest 13 percent return on equity and limited differentiation keep us from seeing anything special.
Competition from larger device makers, hospital budget squeezes and regulatory hurdles all sit in the path. The numbers look reasonable yet nothing here demands attention right now. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GMED trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-31Markup · changed$85.94+7.1%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $109.
2026-07-31Distribution$80.26-0.2%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $109.
2026-07-18Distribution$80.39+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $109.
2026-07-03Distribution$80.39+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$80.39Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
